Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma, T-Cell, Peripheral × Alemtuzumab × Clear all

Phase

Phase 2 5 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 8 Leukemia 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Multiple Myeloma 6 Lymphoma, Non-Hodgkin 6 Myelodysplastic Syndromes 5 Leukemia, Myeloid, Acute 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Hodgkin Disease 4 Neoplasms, Plasma Cell 3 Myeloproliferative Disorders 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Hematologic Neoplasms 3 Paraproteinemias 2 Lymphoproliferative Disorders 2 Lymphoma, Large B-Cell, Diffuse 2 Burkitt Lymphoma 2 Anemia, Aplastic 2 Waldenstrom Macroglobulinemia 1 Shwachman-Diamond Syndrome 1 Sezary Syndrome 1 Recurrence 1 Primary Immunodeficiency Diseases 1 Preleukemia 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neutropenia, Severe Congenital, Autosomal Recessive 3 1 Neuroblastoma 1 Neoplasms 1 Myelodysplastic-Myeloproliferative Diseases 1 Mycosis Fungoides 1

Interventions

romidepsin 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5 Vincristine 3 Prednisone 3 Lenalidomide 3 Gemcitabine 3 Doxorubicin 3 Cyclophosphamide 3 Azacitidine 3 ixazomib 2 fludarabine phosphate 2 Whole-Body Irradiation 2 Peripheral Blood Stem Cell Transplantation 2 Mycophenolic Acid 2 Dexamethasone 2 Cyclosporine 2 Bortezomib 2 10-propargyl-10-deazaaminopterin 2 venetoclax 1 tislelizumab 1 tazemetostat 1 relatlimab 1 pomalidomide 1 navitoclax 1 mogamulizumab 1 gemcitabine-oxaliplatin regimen 1 daratumumab 1 copanlisib 1 carfilzomib 1 camrelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00453427 2015-06-03

ACCAPELA

Ontario Clinical Oncology Group (OCOG)

Phase 1/2 Completed

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡